EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Rating) had its target price boosted by investment analysts at HC Wainwright from $24.00 to $25.00 in a research note issued to investors on Thursday, The Fly reports. HC Wainwright’s target price points to a potential upside of 137.42% from the stock’s current price.
Separately, Chardan Capital assumed coverage on shares of EyePoint Pharmaceuticals in a research report on Thursday, July 7th. They set a “buy” rating and a $21.00 target price for the company. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, EyePoint Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.00.
EyePoint Pharmaceuticals Stock Up 0.2 %
EYPT stock opened at $10.53 on Thursday. The firm has a 50 day moving average of $8.76 and a 200-day moving average of $10.17. The company has a debt-to-equity ratio of 0.17, a quick ratio of 6.77 and a current ratio of 6.87. EyePoint Pharmaceuticals has a 12 month low of $6.99 and a 12 month high of $21.50.
Institutional Investors Weigh In On EyePoint Pharmaceuticals
Hedge funds have recently bought and sold shares of the stock. Essex Investment Management Co. LLC lifted its position in EyePoint Pharmaceuticals by 30.0% during the fourth quarter. Essex Investment Management Co. LLC now owns 224,229 shares of the company’s stock valued at $2,745,000 after purchasing an additional 51,702 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its position in EyePoint Pharmaceuticals by 10.6% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,950,000 shares of the company’s stock valued at $23,868,000 after purchasing an additional 186,969 shares during the last quarter. Samsara BioCapital LLC lifted its holdings in shares of EyePoint Pharmaceuticals by 6.7% in the 4th quarter. Samsara BioCapital LLC now owns 480,000 shares of the company’s stock worth $5,875,000 after acquiring an additional 30,000 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of EyePoint Pharmaceuticals in the 1st quarter worth approximately $30,000. Finally, Suvretta Capital Management LLC lifted its holdings in shares of EyePoint Pharmaceuticals by 47.8% in the 4th quarter. Suvretta Capital Management LLC now owns 2,519,700 shares of the company’s stock worth $30,841,000 after acquiring an additional 815,111 shares during the last quarter. 87.67% of the stock is currently owned by institutional investors.
EyePoint Pharmaceuticals Company Profile
EyePoint Pharmaceuticals, Inc, a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery.
- Get a free copy of the StockNews.com research report on EyePoint Pharmaceuticals (EYPT)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for EyePoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EyePoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.